Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757569 | 0.91 | TSPO (0.58) | TSPO | |
| SCHEMBL13161221 | 0.90 | TSPO (0.54) | TSPO | |
| SCHEMBL2757571 | 0.88 | TSPO (0.68) | TSPO | |
| SCHEMBL241624 | 0.88 | TSPO (0.65) | TSPO | |
| SCHEMBL2757570 | 0.81 | TSPO (0.69) | TSPO | |
| SCHEMBL3268801 | 0.81 | TSPO (0.45) | TSPO | |
| SCHEMBL17974070 | 0.81 | TSPO (1.00) | TSPO | |
| SCHEMBL12691931 | 0.81 | TSPO (1.00) | TSPO | |
| SCHEMBL29424335 | 0.81 | TSPO (1.00) | TSPO | |
| SCHEMBL18116260 | 0.80 | TSPO (0.65) | TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| WO-2010106166-A2 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106166-A2 | ARYLOXYANILIDE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003154-A1 | ARYLOXYANILIDE DERIVATIVES | GABBR1, GABRA4, CNR1 | TSPO 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.